These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17479289)

  • 1. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma.
    Ramankulov A; Lein M; Kristiansen G; Meyer HA; Loening SA; Jung K
    J Cancer Res Clin Oncol; 2007 Sep; 133(9):643-52. PubMed ID: 17479289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum-gamma-glutamyltransferase (GGT) does not represent an independent prognostic factor in a European cohort of patients with non-metastatic renal cell carcinoma.
    Dalpiaz O; Pichler M; Mrsic E; Reitz D; Krieger D; Venturino L; Bezan A; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC
    J Clin Pathol; 2015 Jul; 68(7):547-51. PubMed ID: 25862811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas.
    Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Jung K
    Cancer Sci; 2008 Jun; 99(6):1188-94. PubMed ID: 18422740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma.
    Papworth K; Bergh A; Grankvist K; Ljungberg B; Sandlund J; Rasmuson T
    Acta Oncol; 2013 Jan; 52(1):159-65. PubMed ID: 22731830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma.
    Ramankulov A; Lein M; Johannsen M; Schrader M; Miller K; Loening SA; Jung K
    Cancer Lett; 2008 Sep; 269(1):85-92. PubMed ID: 18504068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
    Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
    BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
    Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
    Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
    Korpela J; Tiitinen SL; Hiekkanen H; Halleen JM; Selander KS; Väänänen HK; Suominen P; Helenius H; Salminen E
    Anticancer Res; 2006; 26(4B):3127-32. PubMed ID: 16886645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
    Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
    Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.
    Ramankulov A; Lein M; Kristiansen G; Loening SA; Jung K
    Prostate; 2007 Feb; 67(3):330-40. PubMed ID: 17192877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of bone sialoprotein in clear cell renal carcinoma.
    Righi L; Bollito E; Ceppi P; Mirabelli D; Tavaglione V; Chiusa L; Porpiglia F; Brunelli M; Martignoni G; Terrone C; Papotti M
    Anticancer Res; 2013 Jun; 33(6):2679-87. PubMed ID: 23749927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma.
    Sim SH; Messenger MP; Gregory WM; Wind TC; Vasudev NS; Cartledge J; Thompson D; Selby PJ; Banks RE
    Br J Cancer; 2012 Sep; 107(7):1131-7. PubMed ID: 22918393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma.
    Hofbauer SL; Stangl KI; de Martino M; Lucca I; Haitel A; Shariat SF; Klatte T
    Br J Cancer; 2014 Oct; 111(8):1526-31. PubMed ID: 25117808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum level of ANGPTL4 as a potential biomarker in renal cell carcinoma.
    Dong D; Jia L; Zhou Y; Ren L; Li J; Zhang J
    Urol Oncol; 2017 May; 35(5):279-285. PubMed ID: 28110976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
    Vanhuyse M; Penel N; Caty A; Fumagalli I; Alt M; Zini L; Adenis A
    Bull Cancer; 2012 Dec; 99(12):100-6. PubMed ID: 23220100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.
    Gravis G; Chanez B; Derosa L; Beuselinck B; Barthelemy P; Laguerre B; Brachet PE; Joly F; Escudier B; Harrison DJ; Laird A; Vasudev N; Ralph C; Larkin J; Lote H; Salem N; Walz J; Thomassin J; Sfumato P; Stewart GD; Boher JM;
    Urol Oncol; 2016 Apr; 34(4):167.e17-23. PubMed ID: 26670200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
    Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
    BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
    Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
    Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.